RECOVER: Post Acute Sequelae of SARS-COV2 (PASC)

Observational study seeking to learn more about LONG COVID—who gets it, what are some of the common and uncommon symptoms, how prevalent it is; gov identifier: NCT05172024

Sponsor: NIH-NHLBI Coordinating Center/CRO: NYU Langone Health Primary objective: Characterize the incidence and prevalence of sequelae of SARS-CoV-2 infection; characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history, and distinct phenotypes identified as sequelae of SARS-CoV-2 infection Study drugs: N/A This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without COVID-19 infection and at varying stages before and after infection. Individuals with and without COVID-19 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC.

This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute COVID-19 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.

Meet Your Clinical Research Team